SCHEMBL13801302

SCHEMBL13801302

CC(C)(C)OC(=O)N1CC[C@@H](NC(=O)c2cc(C(F)(F)F)cc(C(F)(F)F)c2)C(c2ccc(F)c(Cl)c2)C1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 4/20 0.46
STS P08842 1/20 0.44
TACR2 P21452 1/20 0.42
TAC3 Q9UHF0 1/20 0.42
USP30 Q70CQ3 3/20 0.41
HDAC4 P56524 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
TAS1R3 Q7RTX0 1/20 0.41
TAS1R1 Q7RTX1 1/20 0.41
TAS1R2 Q8TE23 1/20 0.41
SPTLC2 O15270 2/20 0.40
TACR3 P29371 1/20 0.40
PDE4B Q07343 1/20 0.40
MAPT P10636 1/20 0.39
CNR1 P21554 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
GPR35 Q9HC97 1/20 0.39
GPR55 Q9Y2T6 1/20 0.39
P2RY14 Q15391 1/20 0.39
RHOC P08134 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13814584 1.00 TACR1 (0.46) TACR1STSTACR2TAC3USP30
SCHEMBL13801285 0.93 TACR3 (0.46) TACR1STSTACR2TAC3USP30
SCHEMBL13814588 0.93 TACR3 (0.46) TACR1STSTACR2TAC3USP30
SCHEMBL13801240 0.93 TACR1 (0.49) TACR1STSTACR2TAC3USP30
SCHEMBL13801311 0.93 TACR1 (0.49) TACR1STSTACR2TAC3USP30
SCHEMBL13801316 0.93 TACR1 (0.49) TACR1STSTACR2TAC3USP30
SCHEMBL4150434 0.93 TACR1 (0.49) TACR1STSTACR2TAC3USP30
SCHEMBL13801289 0.92 TACR1 (0.46) TACR1STSTACR2TAC3USP30
SCHEMBL13814639 0.92 TACR1 (0.46) TACR1STSTACR2TAC3USP30
SCHEMBL13801272 0.92 TACR1 (0.47) TACR1STSUSP30HDAC4HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8470816-B2 Nitrogen-containing heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-25 US disclosed
US-20090156572-A1 Nitrogen-containing heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156572-A1 Nitrogen-containing heterocyclic compound and use thereof NTSR2, NTSR1, HNMT TACR1 9/4885STS 648/4885TACR2 19/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.